


**In the Claims:**

Please cancel claims 1-85.

Please add the following new claims.


86. (New) A compound of the formula (I):



or a salt thereof.

87. (New) The compound of claim 86, wherein the compound of formula (I) is an aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium, or zinc salt.


88. (New) A composition comprising a pharmaceutically acceptable carrier and a compound of the formula (I):



or a salt thereof.

89. (New) The composition of claim 88, wherein the compound of formula (I) is an aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium, or zinc salt.

90. (New) A method for treating a CCR9-mediated condition or disease comprising administering to a subject a therapeutically effective amount of a compound of the formula (I):



or a salt thereof.

91. (New) The method of claim 90, wherein the compound of formula (I) is an aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium, or zinc salt.


92. (New) The method of claim 90, where the CCR9-mediated disease or condition is an inflammatory condition.

93. (New) The method of claim 90, where the CCR9-mediated disease or condition is an immunoregulatory disorder.

94. (New) The method of claim 90, where the CCR9-mediated condition or disease is inflammatory bowel disease.

95. (New) The method of claim 90, where the CCR9-mediated condition or disease is selected from the group consisting of an allergic disease, psoriasis, atopic dermatitis, asthma, fibrotic diseases and graft rejection.

96. (New) The method of claim 90, where the CCR9-mediated condition or disease is selected from the group consisting of immune mediated food allergies and autoimmune diseases.
97. (New) The method of claim 90, where the CCR9-mediated condition or disease is Celiac disease or rheumatoid arthritis.
98. (New) The method of claim 90, where the CCR9-mediated disease or condition is a leukemia or a solid tumor.
99. (New) The method of claim 90, where the CCR9-mediated disease or condition is thymoma or a thymic carcinoma.
100. (New) The method of claim 90, where the CCR9-mediated disease or condition is acute lymphocytic leukemia.
101. (New) The method of claim 90, where the administering is oral, parenteral, rectal, transdermal, sublingual, nasal or topical.
102. (New) The method of claim 90, further comprising administering an anti-inflammatory or analgesic agent.
103. (New) A method of modulating CCR9 function in a cell, comprising contacting the cell with a CCR9 modulating amount of the compound of a compound of the formula (I):



or a salt thereof.

104. (New) The method of claim 103, wherein the compound of formula (I) is an aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium, or zinc salt.